Envestnet Asset Management Inc Cerus Corp Transaction History

Envestnet Asset Management Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 04, 2023	BUY	$1.79 - $2.9 $18,807 - $30,470	10,507 New	10,507 $25,000
Q4 2022 Feb 07, 2023	BUY	$3.38 - $4.22 $3,129 - $3,907	926 Added 8.67%	11,603 $42,000
Q3 2022 Nov 10, 2022	SELL	$3.43 - $5.83 $100,354 - $170,574	-29,258 Reduced 73.26%	10,677 $38,000
Q2 2022 Aug 03, 2022	BUY	$4.41 - $5.69 $176,113 - $227,230	39,935 New	39,935 $211,000
Q2 2020 Jul 08, 2020	SELL	$4.5 - $7.02 $147,816 - $230,592	-32,848 Closed	0 $0
Q1 2020 Apr 23, 2020	BUY	$2.87 - $5.49 $6,009 - $11,496	2,094 Added 6.81%	32,848 $153,000
Q4 2019 Feb 11, 2020	BUY	$3.84 - $4.86 $12,583 - $15,926	3,277 Added 11.93%	30,754 $130,000
Q3 2019 Oct 17, 2019	BUY	$4.86 - $6.05 $11,931 - $14,852	2,455 Added 9.81%	27,477 $142,000
Q2 2019 Aug 02, 2019	BUY	$4.51 - $6.6 $3,071 - $4,494	681 Added 2.8%	25,022 $141,000
Q1 2019 May 10, 2019	BUY	$5.16 - $6.85 $125,599 - $166,735	24,341 New	24,341 $152,000
Q3 2018 Nov 14, 2018	SELL	$6.89 - $7.78 $37,047 - $41,833	-5,377 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	5,377	5,377 $13,000

156

147M

84.2K

55.5K

Ticker CERS
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 177,090,000
Market Cap $351M
Description
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Envestnet Asset Management Inc with notifications on news.